Ovarian Cancer

Basser Executive Director Susan Domchek, MD, discusses the differences between BRCA1 and BRCA2 mutations and explains how the varying risk factors could impact individuals and their families.

Basser Executive Director Susan Domchek, MD, discusses hereditary cancer risk for BRCA mutation carriers and ways in which that might impact individuals differently.

Basser Executive Director Susan Domchek, MD, discusses PARP inhibitors and ways in which they might be combined with other cancer treatments.

Ronny Drapkin, MD, PhD, Basser’s Director of Gynecologic Cancer Research, and Penn’s Ovarian Cancer Research Center shares the latest on early detection research for ovarian cancer.

This 2013 symposium on the Ashkenazi Jewish population's increased chances of carrying a BRCA mutation was moderated by Barbara Walters and featured a panel of breast and ovarian cancer experts, including Basser's Executive Director Susan Domchek, MD.

On Tuesday, May 7, 2019, the Basser Center presented a panel with internationally renowned BRCA experts on the latest in BRCA-related clinical research and patient care. This event was held during the Basser Scientific Symposium and is geared toward the general public.

Men and women of Eastern or Central European Jewish descent (Ashkenazi Jewish) have a 1 in 40 chance of having a BRCA mutation. Learn more about your hereditary cancer risk.

The Basser Center for BRCA's Executive Director, Susan Domchel, MD, sheds some light on BRCA mutations and hereditary cancer.